ArticleInternational journal of hematology2020

Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/day.

Yoshinori Hashimoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.